PL3897655T3 - 3beta-(benzyloksy)-17alfa-metylo-pregn-5-en-20-on do stosowania w leczeniu zaburzeń poznawczych - Google Patents
3beta-(benzyloksy)-17alfa-metylo-pregn-5-en-20-on do stosowania w leczeniu zaburzeń poznawczychInfo
- Publication number
- PL3897655T3 PL3897655T3 PL19831675.4T PL19831675T PL3897655T3 PL 3897655 T3 PL3897655 T3 PL 3897655T3 PL 19831675 T PL19831675 T PL 19831675T PL 3897655 T3 PL3897655 T3 PL 3897655T3
- Authority
- PL
- Poland
- Prior art keywords
- 17alpha
- 3beta
- pregn
- benzyloxy
- methyl
- Prior art date
Links
- IFFPDWXBMZYJMH-DFTYQABXSA-N 1-[(3S,8R,9S,10R,13S,14S,17S)-10,13,17-trimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(C)C(=O)C)CC1=CC=CC=C1 IFFPDWXBMZYJMH-DFTYQABXSA-N 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3897655T3 true PL3897655T3 (pl) | 2025-01-13 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19831675.4T PL3897655T3 (pl) | 2018-12-18 | 2019-12-18 | 3beta-(benzyloksy)-17alfa-metylo-pregn-5-en-20-on do stosowania w leczeniu zaburzeń poznawczych |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP3669876A1 (pl) |
| JP (1) | JP7515480B2 (pl) |
| KR (1) | KR102845328B1 (pl) |
| CN (1) | CN113260366B (pl) |
| AU (1) | AU2019409912B2 (pl) |
| BR (1) | BR112021011654A2 (pl) |
| CA (1) | CA3118210C (pl) |
| CL (1) | CL2021001458A1 (pl) |
| DK (1) | DK3897655T3 (pl) |
| ES (1) | ES2987823T3 (pl) |
| FI (1) | FI3897655T3 (pl) |
| HR (1) | HRP20241376T1 (pl) |
| HU (1) | HUE068626T2 (pl) |
| IL (1) | IL284032B2 (pl) |
| LT (1) | LT3897655T (pl) |
| MA (1) | MA54518B1 (pl) |
| MD (1) | MD3897655T2 (pl) |
| MX (1) | MX2021006904A (pl) |
| PL (1) | PL3897655T3 (pl) |
| PT (1) | PT3897655T (pl) |
| RS (1) | RS66013B1 (pl) |
| SI (1) | SI3897655T1 (pl) |
| SM (1) | SMT202400425T1 (pl) |
| WO (1) | WO2020127468A1 (pl) |
| ZA (1) | ZA202103284B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024085245A1 (ja) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE453620T1 (de) * | 2003-05-01 | 2010-01-15 | Vernalis Res Ltd | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten |
| EP2044029B1 (en) * | 2006-07-14 | 2011-01-26 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| PT2709631T (pt) * | 2011-05-20 | 2017-04-19 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Antagonistas de receptor de cb1 |
| DK2925770T3 (en) * | 2012-11-28 | 2017-04-10 | Univ Bordeaux | 3- (4'-SUBSTITUTED) -BENZYL-ETHER DERIVATIVES OF PREGNENOLONE |
| SMT202000164T1 (it) * | 2013-03-19 | 2020-05-08 | Univ Pompeu Fabra | Antagonisti del recettore cannabinoide cb1 per uso nel trattamento di malattie associate con anomalie dendritiche neuronali |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL271117B (en) | Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders | |
| IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
| SG11202100092QA (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
| IL265635A (en) | Combined treatments including imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL284032A (en) | 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
| GB201812276D0 (en) | Treatment of cognitive disorders | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820451D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820452D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201809408D0 (en) | Treatment of Cognitive Disorders | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido |